Vietnam has set a target of becoming a high-value pharmaceutical production center in the region under its strategy for the development of the pharmaceutical sector by 2030 with a vision to 2045.
Under the strategy, which was approved by Deputy Prime Minister Tran Hong Ha on October 9, Vietnam will strive to develop its pharmaceutical industry to be on par with those in advanced countries in the region while ensuring people’s access to medicines at affordable prices.
It will improve its research capacity and optimize existing technologies to produce generic medicines and modern dosage forms, a part of becoming a center for the technology transfer and manufacture of generic drugs in ASEAN.
Vietnam also targets the mass production of pharmaceuticals and products from domestic medicinal resources with high quality and value, and will boost the production of raw materials.
Other goals under strategy include achieving WHO certification at Level 3 or higher in the capacity of State management over pharmaceutical products, and maintain and upgrade WHO certification on the capacity of State management over vaccines.
All pharmaceutical businesses meeting good manufacturing practice (GMP) standards will be maintained, while all drug and vaccine testing facilities are to follow good laboratory practice (GLP) principles.